Vivani Medical, Inc.
VANIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeVivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The $104.6M market capitalization puts VANI squarely in micro-cap range for its industry. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases.
Market Cap
$104.6M
Beta
3.30
P/E (TTM)
—
P/E (Fwd)
-3.31
EPS (TTM)
$-0.36
EPS (Fwd)
$-0.35
ROE
-220.4%
ROA
-48.5%
Cash
$19.9M
Total Debt
$17.9M
Free CF
-$16.8M
52W Change
-30.5%
Annual Financials
Cash vs Debt
Where VANI stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, VANI finished 11.11% below its 150-day moving average ($1.26) and 11.11% below its 200-day moving average ($1.26). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VANI overbought or oversold?
At the October 19, 2026 close, VANI's RSI(14) was 29.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $19.9M in cash comfortably exceeding the $17.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$16.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -220.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Vivani Medical, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VANI.